GAITHERSBURG, Md.--(BUSINESS WIRE)--MaxCyte, Inc., the pioneer in scalable, high performance cell loading systems, is hosting a series of events at the 2nd Annual Society for Laboratory Automation and Screening (SLAS) Conference and Exhibition to be held January 13-16, in Orlando, FL. MaxCyte will conduct a tutorial, present a scientific poster, and schedule one-on-one discussions in Booth #428 to demonstrate how the MaxCyte Scalable Transfection Systems can improve the physiological relevance and quality of cellular screening campaigns.
“Development of Fully Scalable Reporter Gene Assays for Studying Transcriptional Regulation & Receptor Activation Using Flow Electroporation”
At the conference, MaxCyte will conduct a tutorial entitled “Streamlined Receptor Screening: Ion Channels, GPCRs and Transporter Screening in Biologically Relevant Cells Using Large-Scale Transient Transfection” on Tuesday, January 15, 2013, at 12:30 PM in rooms Gainesville 1-2 at the Gaylord Palms Resort & Convention Center. In this tutorial, Dr. James Brady, Director of Technical Applications at MaxCyte, will present specific case studies from around the world demonstrating the broad cell type compatibility of the MaxCyte STX, including stem cells, primary cells, insect cells, and other difficult-to-transfect cell lines, along with the performance of these transfected cells in downstream applications for cell-based screening and protein production. Highlighted in Dr. Brady’s presentation will be the complementary performance of the MaxCyte flow electroporation technology with downstream assay platforms.
MaxCyte will also present a scientific poster entitled “Development of Fully Scalable Reporter Gene Assays for Studying Transcriptional Regulation & Receptor Activation Using Flow Electroporation” (poster # MP 163). MaxCyte scientists will be available at this poster on Monday, January 14, from 1:00 to 3:00 PM for further discussion of these data.
MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. Drawing on its cell therapy expertise, MaxCyte designed a portfolio of products including the MaxCyte STX® Scalable Transfection System and MaxCyte VLX® Large Scale Transfection System, ideal tools for use in drug discovery research and screening and protein production environments. These products provide for the rapid development and consistent production of billions of (co)transfected primary cells, stem cells, and cell lines for protein and antibody production and for cell-based assays with comparable results and Seamless Scalability™ from the bench to HTS and pilot and production scale.
For more information, http://www.maxcyte.com.